Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Patents and Intellectual Property Rights on February 14, 2006
In a revised, expanded agreement, Amgen receives exclusive worldwide rights to develop and commercialize Biovitrum's drug candidate for Type 2 diabetes and related metabolic Diseases. Previously, Amgen had exclusive rights to commercialize products only in North and South America, the European Union, Australia and New Zealand.
Biovitrum's lead compound, 11beta-HSD1 enzyme inhibitors, are currently under early clinical development.
Tags: diabetes amgen biotech type rights type+diabetes biovitrum+lead candidate+type
Vote for Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:
|
Rating: 6.00 out of 1 vote(s) cast.
|
Response from:
James Hatton
(02/16/06 8:26am)
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
When they signed the 2003 license (the winner of the "Best of Biotech 2004" award for "Most Creative and Significant Deal"), the September 8, 2003 press release disclosed that the license fee was $87 million.